Patient characteristics in the histology set
| . | Histology set n = 194 . |
|---|---|
| Age, y (median [min-max]) | 33 [18-68] |
| Age >60 y | 6 (3.1%) |
| Female | 116 (59.8%) |
| ECOG performance status score of 0 to 1 | 161 (84.7%) |
| Ann Arbor stage I to II | 110 (56.7%) |
| Presence of an anterior mediastinal involvement | 194 (100%) |
| Elevated LDH level | 161 (83.0%) |
| IPI 0 | 20 (10.6%) |
| IPI 1 to 2 | 119 (63.3%) |
| IPI 3 to 5 | 49 (26.1%) |
| Baseline median MTV, cm3 (min-max) | 300.4 (2.5-1403.6) |
| MTV ≥360 cm3 | 59 (39.9%) |
| Maximal median mediastinal mass diameter, mm (min-max) | 100 (10-180) |
| Bulky mass ≥10 cm | 113 (58.9%) |
| Extranodal involvement | 98 (50.8%) |
| Firstline treatment | |
| Anti-CD20 + ACVBP | 113 (58.2%) |
| Anti-CD20 + CHOP14 | 49 (25.3%) |
| Anti-CD20 + CHOP21 | 32 (16.5%) |
| Median follow-up, mo (min-max) | 51.3 (1-152.7) |
| . | Histology set n = 194 . |
|---|---|
| Age, y (median [min-max]) | 33 [18-68] |
| Age >60 y | 6 (3.1%) |
| Female | 116 (59.8%) |
| ECOG performance status score of 0 to 1 | 161 (84.7%) |
| Ann Arbor stage I to II | 110 (56.7%) |
| Presence of an anterior mediastinal involvement | 194 (100%) |
| Elevated LDH level | 161 (83.0%) |
| IPI 0 | 20 (10.6%) |
| IPI 1 to 2 | 119 (63.3%) |
| IPI 3 to 5 | 49 (26.1%) |
| Baseline median MTV, cm3 (min-max) | 300.4 (2.5-1403.6) |
| MTV ≥360 cm3 | 59 (39.9%) |
| Maximal median mediastinal mass diameter, mm (min-max) | 100 (10-180) |
| Bulky mass ≥10 cm | 113 (58.9%) |
| Extranodal involvement | 98 (50.8%) |
| Firstline treatment | |
| Anti-CD20 + ACVBP | 113 (58.2%) |
| Anti-CD20 + CHOP14 | 49 (25.3%) |
| Anti-CD20 + CHOP21 | 32 (16.5%) |
| Median follow-up, mo (min-max) | 51.3 (1-152.7) |
Confirmed PMBL cases after expert pathologic review, n = 194.
ECOG, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; max, maximum; min, minimum.